Vitrolife AB (publ) (VITR.ST)
SEK 214.4
(1.13%)
SEK 214.4
(1.13%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.51 Billion SEK | 8.6% |
| 2022 | 3.23 Billion SEK | 92.41% |
| 2021 | 1.68 Billion SEK | 34.94% |
| 2020 | 1.24 Billion SEK | -15.85% |
| 2019 | 1.48 Billion SEK | 28.56% |
| 2018 | 1.15 Billion SEK | 10.05% |
| 2017 | 1.04 Billion SEK | 22.21% |
| 2016 | 856.1 Million SEK | 18.51% |
| 2015 | 722.37 Million SEK | 41.5% |
| 2014 | 510.51 Million SEK | 12.76% |
| 2013 | 452.73 Million SEK | 25.06% |
| 2012 | 362.02 Million SEK | 1.66% |
| 2011 | 356.11 Million SEK | 19.68% |
| 2010 | 297.56 Million SEK | 8.35% |
| 2009 | 274.62 Million SEK | 21.98% |
| 2008 | 225.14 Million SEK | 19.16% |
| 2007 | 188.93 Million SEK | 10.32% |
| 2006 | 171.26 Million SEK | 42.58% |
| 2005 | 120.12 Million SEK | 15.66% |
| 2004 | 103.85 Million SEK | 7.89% |
| 2003 | 96.25 Million SEK | -6.8% |
| 2002 | 103.28 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 941 Million SEK | 11.89% |
| 2024 Q1 | 841 Million SEK | -6.97% |
| 2024 Q3 | 867 Million SEK | -7.86% |
| 2023 FY | 3.51 Billion SEK | 8.6% |
| 2023 Q1 | 854 Million SEK | -0.12% |
| 2023 Q2 | 905 Million SEK | 5.97% |
| 2023 Q3 | 848 Million SEK | -6.3% |
| 2023 Q4 | 904 Million SEK | 6.6% |
| 2022 Q2 | 829 Million SEK | 10.24% |
| 2022 Q1 | 752 Million SEK | 46.24% |
| 2022 Q3 | 798 Million SEK | -3.74% |
| 2022 Q4 | 855 Million SEK | 7.14% |
| 2022 FY | 3.23 Billion SEK | 92.41% |
| 2021 Q1 | 378.95 Million SEK | -0.9% |
| 2021 Q2 | 382.04 Million SEK | 0.82% |
| 2021 Q4 | 514.23 Million SEK | 26.79% |
| 2021 FY | 1.68 Billion SEK | 34.94% |
| 2021 Q3 | 405.56 Million SEK | 6.16% |
| 2020 Q4 | 382.38 Million SEK | 19.44% |
| 2020 FY | 1.24 Billion SEK | -15.85% |
| 2020 Q2 | 209.16 Million SEK | -37.35% |
| 2020 Q3 | 320.14 Million SEK | 53.06% |
| 2020 Q1 | 333.87 Million SEK | -18.47% |
| 2019 Q3 | 377.99 Million SEK | -0.72% |
| 2019 Q4 | 409.48 Million SEK | 8.33% |
| 2019 Q2 | 380.73 Million SEK | 22.06% |
| 2019 FY | 1.48 Billion SEK | 28.56% |
| 2019 Q1 | 311.92 Million SEK | -2.56% |
| 2018 Q4 | 320.11 Million SEK | 12.71% |
| 2018 Q2 | 283.23 Million SEK | 7.29% |
| 2018 Q3 | 284.01 Million SEK | 0.28% |
| 2018 Q1 | 263.99 Million SEK | -2.53% |
| 2018 FY | 1.15 Billion SEK | 10.05% |
| 2017 Q4 | 270.84 Million SEK | 10.14% |
| 2017 FY | 1.04 Billion SEK | 22.21% |
| 2017 Q2 | 285.38 Million SEK | 16.92% |
| 2017 Q1 | 244.08 Million SEK | -2.72% |
| 2017 Q3 | 245.9 Million SEK | -13.83% |
| 2016 Q3 | 210.42 Million SEK | 1.28% |
| 2016 FY | 856.1 Million SEK | 18.51% |
| 2016 Q1 | 186.99 Million SEK | -6.04% |
| 2016 Q2 | 207.77 Million SEK | 11.11% |
| 2016 Q4 | 250.9 Million SEK | 19.24% |
| 2015 FY | 722.37 Million SEK | 41.5% |
| 2015 Q4 | 199.02 Million SEK | 12.57% |
| 2015 Q1 | 162.39 Million SEK | 18.66% |
| 2015 Q2 | 184.14 Million SEK | 13.39% |
| 2015 Q3 | 176.8 Million SEK | -3.99% |
| 2014 Q2 | 129.43 Million SEK | 8.7% |
| 2014 Q1 | 119.07 Million SEK | -3.59% |
| 2014 FY | 510.51 Million SEK | 12.76% |
| 2014 Q4 | 136.85 Million SEK | 9.36% |
| 2014 Q3 | 125.14 Million SEK | -3.32% |
| 2013 FY | 452.73 Million SEK | 25.06% |
| 2013 Q2 | 115.99 Million SEK | 10.88% |
| 2013 Q1 | 104.6 Million SEK | 6.8% |
| 2013 Q3 | 108.64 Million SEK | -6.34% |
| 2013 Q4 | 123.5 Million SEK | 13.68% |
| 2012 FY | 362.02 Million SEK | 1.66% |
| 2012 Q3 | 82.92 Million SEK | -12.91% |
| 2012 Q4 | 97.94 Million SEK | 18.12% |
| 2012 Q1 | 99.72 Million SEK | 4.56% |
| 2012 Q2 | 95.22 Million SEK | -4.51% |
| 2011 Q1 | 88.03 Million SEK | 8.64% |
| 2011 FY | 356.11 Million SEK | 19.68% |
| 2011 Q4 | 95.37 Million SEK | 12.13% |
| 2011 Q3 | 85.05 Million SEK | -2.97% |
| 2011 Q2 | 87.65 Million SEK | -0.43% |
| 2010 Q1 | 75.27 Million SEK | 11.76% |
| 2010 Q2 | 73.4 Million SEK | -2.48% |
| 2010 Q3 | 67.84 Million SEK | -7.58% |
| 2010 Q4 | 81.03 Million SEK | 19.43% |
| 2010 FY | 297.56 Million SEK | 8.35% |
| 2009 FY | 274.62 Million SEK | 21.98% |
| 2009 Q2 | 70.17 Million SEK | 0.0% |
| 2009 Q4 | 67.35 Million SEK | 3.24% |
| 2009 Q3 | 65.24 Million SEK | -7.03% |
| 2008 FY | 225.14 Million SEK | 19.16% |
| 2007 FY | 188.93 Million SEK | 10.32% |
| 2006 FY | 171.26 Million SEK | 42.58% |
| 2005 FY | 120.12 Million SEK | 15.66% |
| 2004 FY | 103.85 Million SEK | 7.89% |
| 2003 FY | 96.25 Million SEK | -6.8% |
| 2002 FY | 103.28 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -56173.033% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | -155.79% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | -155.79% |
| Arcoma AB | 163.01 Million SEK | -2054.403% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | -1621.653% |
| BICO Group AB (publ) | 2.23 Billion SEK | -56.821% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | -514.707% |
| CellaVision AB (publ) | 677.29 Million SEK | -418.536% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | -42351.348% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -359632.495% |
| C-Rad AB (publ) | 424.61 Million SEK | -727.102% |
| Duearity AB (publ) | 1.65 Million SEK | -212233.736% |
| Dignitana AB (publ) | 86.06 Million SEK | -3980.732% |
| Episurf Medical AB (publ) | 10.3 Million SEK | -33997.087% |
| Getinge AB (publ) | 31.82 Billion SEK | 88.965% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | -49516.517% |
| Integrum AB (publ) | 104.11 Million SEK | -3273.075% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -410804.892% |
| Mentice AB (publ) | 273.61 Million SEK | -1183.579% |
| OssDsign AB (publ) | 112.15 Million SEK | -3031.325% |
| Paxman AB (publ) | 210.11 Million SEK | -1571.45% |
| Promimic AB (publ) | 37.07 Million SEK | -9373.968% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -1439244.262% |
| SciBase Holding AB (publ) | 23.24 Million SEK | -15008.626% |
| ScandiDos AB (publ) | 60.42 Million SEK | -5711.779% |
| Sectra AB (publ) | 2.96 Billion SEK | -18.504% |
| Sedana Medical AB (publ) | 153.86 Million SEK | -2182.491% |
| Senzime AB (publ) | 35.75 Million SEK | -9722.677% |
| SpectraCure AB (publ) | 318 Thousand SEK | -1104302.516% |
| Stille AB | 294.89 Million SEK | -1090.94% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | -487.741% |